Navigation Links
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
Date:6/8/2009

y combination of these agents were eligible for enrollment and immediately switched to a starting dose of 6.0 grams per day of Zerenex (ferric citrate). Patients were treated with Zerenex (ferric citrate) for four weeks and were titrated weekly to achieve and maintain normal serum phosphorus levels, between 3.5 to 5.5 mg/dL, the therapeutic goal.

Although designed primarily as a safety study, key efficacy parameters were evaluated, with results as follows:

At baseline:

  • Baseline mean + standard deviation (SD) serum phosphorus was approximately 5.9 + 1.5 mg/dL immediately prior to the switch to Zerenex (ferric citrate);
  • The average daily dose of PhosLo(R) (calcium acetate) was 6.9 grams per day and for Renagel(R) (sevelamer hydrochloride) was 9.9 grams per day, for patients not on combination therapy prior to the switch to Zerenex (ferric citrate).

Following the treatment period (four weeks on Zerenex):

  • At the end of the treatment period (after four weeks on Zerenex) the mean + SD serum phosphorus was approximately 5.4 + 1.3 mg/dL;
  • The average daily dose of Zerenex (ferric citrate) at the end of four weeks of treatment was 6.8 grams per day.

In the subset of patients who had a serum phosphorus above the normal range (> 5.5 mg/dL) immediately prior to the switch to Zerenex (n = 29), the mean (SD) baseline serum phosphorus was 7.0 (1.1) mg/dL, and at the end of treatment with Zerenex the mean (SD) serum phosphorus was 5.6 (1.6) mg/dL.

In the Phase 2 study, there were four serious adverse events which were deemed unrelated to Zerenex. Darkened stool was reported in the study and was associated with the presence of iron in the gastrointestinal tract. With the exception of the reporting of darkened stool
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... SAN DIEGO , March 26, 2015  BioNano ... the appointment of  Terry Salyer as chief commercial ... building highly effective, worldwide sales teams in life sciences. ... Irys ® System, a genome-mapping platform to assemble ... and investigate structural variations. To date, 32 institutions located ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 ReliantHeart, Inc., ... and Transonic, a supplier of precision transit-time flow measurement ... will greatly improve the efficiency of the HeartAssist5® ... LVAD patients to experience greater mobility and peace of ... the miniature flow board, will draw 1/6th of the ...
(Date:3/25/2015)... Russia,s pharmaceutical market is one of the ... to its absolute size, plus a growing economy and ... from Business Monitor International. The Russian market is set ... pharmaceutical market, with growth estimates around 10-15% annually reaching ... About Green Cross Green Cross ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... Bloodstream- Data Demonstrates Sustained Release and Increased ... Phosphagenics Limited ("Phosphagenics") (ASX: POH; OTCQX: ... preclinical studies related to its patented TPM/oxycodone ... preclinical studies demonstrated that by incorporating TPM/oxycodone ...
... Exiqon Diagnostics, announced today a strategic commercial partnership ... solution provider for oncologists that offers clinically useful ... Exiqon Diagnostics, a leader in individualizing cancer ... EDR(R) Assay) clinical laboratory services, will become a ...
... L.P., a subsidiary of Mylan Inc. (Nasdaq: ... market and distribute EMSAM(R) in the U.S. EMSAM, a ... which was approved by the U.S. Food and Drug ... depressive disorder. EMSAM previously was marketed and distributed by ...
Cached Biology Technology:Phosphagenics Announces Completion of Transdermal Patch Prototypes 2Phosphagenics Announces Completion of Transdermal Patch Prototypes 3Phosphagenics Announces Completion of Transdermal Patch Prototypes 4Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists 2Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists 3Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder 2
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... March 12, 2015 The mascots of the ... Hospital, part of Wake Forest Baptist Medical Center. They ... the 2015 ACC Men,s Basketball Tournament. Young patients enjoyed ... and getting their autographs. Brenner Children,s Hospital ... is the only children,s hospital in northwest ...
(Date:3/11/2015)...   The Sync Project™ today announced ... and harness music to improve health. The platform ... measurements of physiology, enabling the study of the ... populations. It is designed for medical and health ... studies and accelerate the discovery of the clinical ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... into our brain, and new research by University of ... known that fear and other highly emotional experiences lead ... today (Tuesday, June 14) in advance of publication in ... Kaufer and colleagues report a new way for emotions ...
... , This release is available in Spanish ... mixes are a produce section favorite. They offer convenience, selection, ... from the chore of washing and chopping, slicing, or shredding ... time to time, been associated with bagged salad greens. The ...
... to replace lost teeth with titanium dental implants could be ... only at micro level but also at nano level, researchers ... a method that could shorten the healing time for patients. ... the conductivity of the implant allows us to affect the ...
Cached Biology News:Fear boosts activation of young, immature brain cells 2Fear boosts activation of young, immature brain cells 3Scientists pitch in to help keep salad mixes safe to eat 2Healing times for dental implants could be cut 2
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... cleaning agent for removing RNase ... and pipettors. It is ... contamination from microcentrifuge tubes without ... Zap (R) is ...
Mol wt: average mol wt12,360.96 Da by calculation...
... of a series of media originally developed at ... al. for the large scale propagation of cells ... primarily used for the growth and maintenance of ... of viruses in these cell lines. One of ...
Biology Products: